However, our Western blot and IF analyses clearly show that GEN treatment reduces cytoplasmic levels Bcl-xL as well as increases nuclear Bcl-xL levels in NSCLC cells. This evidence concerns the gene BCL2L1 and non-small cell lung carcinoma.